返回 Agenda
Session 3: Impact of US FDA Final Naming Guidance for Biologics
Session Chair(s)
Hillel P Cohen, PhD
Executive Director, Scientific Affairs
Sandoz Inc., United States
In January 2017, the FDA issued a Final Guidance on the naming of biologics, including originator biologic medicines and biosimilars. The FDA is developing plans to roll out this new naming convention both prospectively and retrospectively. Likewise, numerous stakeholders throughout the US health care system have already or will adapt their current processes to accommodate the Final Guidance. This session will explore considerations for implementing the new system and provide an overview of some of these plans.
Learning Objective :
Speaker(s)
Speaker
Kellie Taylor
FDA, United States
Associate Director, OMEPRM, OSE, CDER, FDA
Speaker
Thomas Felix, MD
Amgen Inc., United States
Medical Director, R&D Policy, Global Regulatory Affairs and Safety
Speaker
Tammy P Powell, MLIS, MS
National Library of Medicine, United States
Health Program Specialist
Speaker
Gerald McEvoy, PharmD
American Society of Health-System Pharmacists, United States
Assistant Vice President of Drug Information